Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
05 mars 2024 07h00 HE
|
Oxford BioMedica plc
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...
Oxford Biomedica completes acquisition of ABL Europe
29 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple...
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
23 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...
Business Update
07 déc. 2023 07h00 HE
|
Oxford BioMedica plc
Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
04 déc. 2023 07h04 HE
|
Oxford BioMedica plc
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
20 sept. 2023 07h46 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
20 sept. 2023 07h41 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica to host webinar showcasing the TetraVecta™ system
07 sept. 2023 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs
14 sept. 2022 07h00 HE
|
Oxford Biomedica Solutions LLC
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Bedford, Massachusetts – September 14, 2022: Oxford Biomedica Solutions LLC, an Oxford...
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
11 mars 2022 07h00 HE
|
Oxford BioMedica plc
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc...